PFS. Data show PFS according to FCGR2A 131 (A), FCGR2B 232 (B), and FCGR3A 158 (C) SNP genotype for patients with DLBCL treated with rituximab (R) or obinutuzumab (G) plus chemotherapy in the GOYA trial.